MedTrace Logo

Lesinurad Tablet Relative Bioavailability

NCT01986556 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2014-09-22

No results posted yet for this study

Summary

This study will assess the relative bioavailability of lesinurad tablets, manufactured at two different sites.

Conditions

  • Healthy

Interventions

DRUG

Lesinurad 400 mg (Site 1)

DRUG

Lesinurad 400 mg (Site 2, Lot A)

DRUG

Lesinurad 400 mg (Site 2, Lot B)

Sponsors & Collaborators

  • Ardea Biosciences, Inc.

    lead INDUSTRY

Principal Investigators

  • J. Hall, MD · Ardea Biosciences, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-11-30
Primary Completion
2014-04-30
Completion
2014-05-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01986556 on ClinicalTrials.gov